Media ReleasesImugene Limited

View All Imugene Limited News


Imugene announces Medical University Vienna presents positive new data on PD-1 mimotope cancer vaccines at the American Association for Cancer Research 2019 Annual Meeting

SYDNEY, Australia, 3 April 2019: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, together with the Medical University Vienna today presented positive new data on the PD-1 mimotope cancer vaccine program at the American Association for Cancer Research (AACR) 2019 Annual Meeting.


For further information please download PDF attached:
Download this document